GSK presents Phase 2b data on linerixibat for the treatment of ...

Linerixibat is an investigational product for the treatment of cholestatic pruritus in patients with PBC and it is not currently approved for ...

A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in ...

GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus · Authors · Affiliations.

GSK presents scientific advances to improve patient outcomes at the ...

Key data include the first oral presentation of full results from the B-Together phase IIb trial investigating bepirovirsen followed by ...

GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of ...

Monthly itch score. Change from baseline in monthly itch score (post hoc) showed a significant difference between placebo and linerixibat 180 mg ...

A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in ...

GLIMMER was a global randomized, placebo-controlled, Phase 2b study (NCT02966834; GSK study 201000) of patients with PBC and moderate-to-severe pruritus (≥4 on ...

Press release | GSK

New data will be presented from the B-CLEAR phase IIb trial evaluating virally supressed patients exploring the association between genotype, ...

GSK to present new data from the B-Clear phase IIb trial for ...

Linerixibat is an investigational product for the treatment of cholestatic pruritus in patients with PBC, currently enrolling the GLISTEN phase ...

Investigation of linerixibat 40 mg BID for cholestatic pruritus of ...

further data from the Phase 2b GLIMMER study to support the Phase 3 GLISTEN study. References. 1. Hegade S, et al. Clin Gastroenterol Hepatol ...

GSK highlights key data from hepatology portfolio at the AASLD's ...

Linerixibat is an ileal bile acid transporter (IBAT) inhibitor, a targeted oral agent with potential to treat cholestatic pruritus (itch) ...

A global Phase IIb study of linerixibat for the treatment of cholestatic ...

In the Japanese and overall populations, on-treatment drug-related adverse events were reported in 25% and 19% of patients in the placebo group and 0%-86% and ...

linerixibat (GSK2330672) News - LARVOL Sigma

The effects of an intestine-restricted ASBT inhibitor GSK2330672 (GSK) or AAV-TBG-FGF15 treatment alone or in combination for 4 weeks on bile acid pool and ...

A global Phase IIb study of linerixibat for the treatment of cholestatic ...

vious use of cholestyramine or other bile acid sequestrants (GSK data on file). This is further supported by data from the post hoc analysis.

A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in ...

Following 4 weeks single-blind placebo, patients with NRS ≥3 were randomized (4:1) to double-blind linerixibat/placebo for 12 weeks (to Week 16) ...

Health Technology Briefing February 2023

3. GlaxoSmithKline. GSK presents Phase 2b data on linerixibat for the treatment of cholestatic pruritus in primary biliary cholangitis (PBC). 2020. Available ...

Linerixibat may relieve itch in primary biliary cholangitis-associated ...

In addition, treatment with linerixibat reduced bile acid levels and improved sleep interference and fatigue compared with placebo. To expand on ...

GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of ...

Linerixibat has the potential to treat cholestatic pruritus in patients with PBC, addressing a major unmet need for this patient population.

Relationship between pruritus and sleep in participants with primary ...

Linerixibat is an ileal bile acid transporter inhibitor in clinical development for the treatment of pruritus associated with PBC and was ...

What is the current valuation of GSK's Linerixibat

Linerixibat is a small molecule commercialized by GSK, with a leading Phase III program in Pruritus. According to Globaldata, it is involved ...

Linerixibat in Healthy Male Volunteers

Information on GSK's data ... linerixibat oral solution during treatment period 2; ... These results have a direct impact on late-stage clinical development of ...

Poster No. 1748 - PosterSessionOnline

Improvement in itch correlates with improved sleep in GLIMMER, a Phase 2b trial of linerixibat for the treatment ... This study was funded by GlaxoSmithKline (GSK ...